DV
Dividend Vision

AUTL — Autolus Therapeutics Ltd

Autolus Therapeutics Ltd (AUTL)

Total return is -91.4% over the past 8.1 years, 310.6 points behind SPY at 219.2%. Its deepest 1-year drawdown was 39.5%.

AUTL is an individual equity stock rather than a diversified ETF fund. As a clinical-stage biopharmaceutical company, it does not currently distribute dividends to shareholders. The stock is oriented toward investors seeking exposure to the biotechnology sector with a focus on cell therapy development, though it carries the concentration risk and volatility typical of early-stage therapeutic companies.

AUTL key facts

Asset type
Stock
Asset class
Equity
Inception date
06/22/2018
Last close
$2.15
Market cap
$383,246,336
Average volume
2395470.0
Beta
1.995
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.09